Abstract
Combinations of biomarkers perform better than single biomarkers for predicting pre-eclampsia, but require external validation before they can be used routinely Potentially effective interventions to prevent pre-eclampsia in patients at risk include early administration of low-dose aspirin or L-arginine in combination with oral antioxidants (vitamins C and E) Maternal plasma levels of angiogenic and antiangiogenic factors identify most patients who will develop early pre-eclampsia, correlate with disease severity and have prognostic value for maternal and/or perinatal complications Management of pre-eclampsia includes control of hypertension, prevention of seizures and timely delivery; steroids are administered to enhance fetal lung maturity if induction of labour before 34 weeks is contemplated In pre-eclampsia at ≥37 weeks of gestation, delivery effectively optimizes pregnancy outcomes; for preterm gestations, the risk of continued pregnancy must be balanced against that of premature birth Women with pre-eclampsia are at increased risk of developing cardiovascular disease, including chronic hypertension, stroke, coronary artery disease, diabetes and end-stage renal disease later in life

This publication has 139 references indexed in Scilit: